Lemos Isabel, Freitas-Dias Catarina, Hipólito Ana, Ramalho José, Carteni Fabrizio, Gonçalves Luís G, Mazzoleni Stefano, Serpa Jacinta
iNOVA4Health, NOVA Medical School, Faculdade de Ciências Médicas, Universidade NOVA de Lisboa, Campo dos Mártires da Pátria, 130, 1169-056 Lisbon, Portugal.
Instituto Português de Oncologia de Lisboa Francisco Gentil (IPOLFG), Rua Prof Lima Basto, 1099-023 Lisbon, Portugal.
Metabolites. 2025 Apr 2;15(4):244. doi: 10.3390/metabo15040244.
The cell-free DNA (cfDNA) is an extracellular fragmented DNA found in body fluids in physiological and pathophysiological contexts. In cancer, cfDNA has been pointed out as a marker for disease diagnosis, staging, and prognosis; however, little is known about its biological role. The role of cfDNA released by ES-2 ovarian cancer cells was investigated, along with the impact of glucose bioavailability and culture duration in the cfDNA-induced phenotype. The effect of cfDNA on ES-2 cell proliferation was evaluated by proliferation curves, and cell migration was assessed through wound healing. We explored the impact of different cfDNA variants on ES-2 cells' metabolic profile using nuclear magnetic resonance (NMR) spectroscopy and cisplatin resistance through flow cytometry. Moreover, we assessed the protein levels of DNA-sensitive Toll-like receptor 9 (TLR9) by immunofluorescence and its colocalization with lysosome-associated membrane protein 1 (LAMP1). This study demonstrated that despite inducing similar effects, different variants of cfDNA promote different effects on cells derived from the ES-2 cell line. We observed instant reactions of adopting the metabolic profile that brings back the cell functioning of more favorable culture conditions supporting proliferation and resembling the cell of origin of the cfDNA variant, as observed in unselected ES-2 cells. However, as a long-term selective factor, certain cfDNA variants induced quiescence that favors the chemoresistance of a subset of cancer cells. Therefore, different tumoral microenvironments may generate cfDNA variants that will impact cancer cells differently, orchestrating the disease fate.
游离DNA(cfDNA)是在生理和病理生理背景下存在于体液中的细胞外片段化DNA。在癌症中,cfDNA已被指出可作为疾病诊断、分期和预后的标志物;然而,人们对其生物学作用知之甚少。本研究调查了ES-2卵巢癌细胞释放的cfDNA的作用,以及葡萄糖生物利用度和培养持续时间对cfDNA诱导表型的影响。通过增殖曲线评估cfDNA对ES-2细胞增殖的影响,并通过伤口愈合实验评估细胞迁移情况。我们使用核磁共振(NMR)光谱法探索了不同cfDNA变体对ES-2细胞代谢谱的影响,并通过流式细胞术评估了顺铂耐药性。此外,我们通过免疫荧光评估了DNA敏感的Toll样受体9(TLR9)的蛋白水平及其与溶酶体相关膜蛋白1(LAMP1)的共定位。本研究表明,尽管诱导了相似的效应,但不同变体的cfDNA对源自ES-2细胞系的细胞具有不同的影响。我们观察到细胞会立即采用代谢谱,恢复支持增殖的更有利培养条件下的细胞功能,并类似于cfDNA变体的起源细胞,这在未筛选的ES-2细胞中也有观察到。然而,作为一种长期的选择因素,某些cfDNA变体诱导细胞静止,这有利于一部分癌细胞的化学抗性。因此,不同的肿瘤微环境可能会产生对癌细胞有不同影响的cfDNA变体,从而决定疾病的命运。